Document:

<PAGE>

                                                                     EXHIBIT 4.4

                         SECURITIES PURCHASE AGREEMENT

      This Securities Purchase Agreement (this "AGREEMENT") is dated as of
January 25, 2005, among JMAR Technologies, Inc., a Delaware corporation (the
"COMPANY"), and PointSource Technologies, LLC, a Delaware limited liability
company, (the "INVESTOR").

      WHEREAS, in consideration of the license rights and other property
granted pursuant to the License Agreement (as defined below), and subject to
the terms and conditions set forth in this Agreement and pursuant to
Section 4(2) of the Securities Act (as defined below) and Rule 506 promulgated
thereunder, the Company desires to issue to the Investor, and the Investor
desires to acquire from the Company certain securities of the Company, as more
fully described in this Agreement.

      NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in
this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and the Investor agree
as follows:

      1.    Definitions

            (a)   Definitions.  In addition to the terms defined elsewhere in
this Agreement, for all purposes of this Agreement, the following terms shall
have the meanings indicated in this Section 1:

      "ACTION" means any action, suit, inquiry, notice of violation, proceeding
(including any partial proceeding such as a deposition) or investigation
pending or threatened in writing against or affecting the Company, any
Subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency, regulatory authority
(federal, state, county, local or foreign), stock market, stock exchange or
trading facility.

      "AFFILIATE" means any Person that, directly or indirectly through one or
more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 144.

      "BUSINESS DAY" means any day except Saturday, Sunday and any day which is
a federal legal holiday or a day on which banking institutions in the State of
New York are authorized or required by law or other governmental action to
close.

      "CLOSING DATE" means the date of the Closing.

      "COMMISSION" means the Securities and Exchange Commission.

      "COMMON STOCK" means the common stock of the Company, par value $0.01 per
share, and any securities into which such common stock may hereafter be
reclassified.

      "COMPANY COUNSEL" means Joseph G. Martinez, Senior Vice President and
General Counsel of the Company.

                                       1
<PAGE>

      "COMPANY DELIVERABLES" has the meaning set forth in Section 2(b)(i).

      "DISCLOSURE MATERIALS" has the meaning set forth in Section 3(a)(viii).

      "EFFECTIVE DATE" means the date that the Registration Statement required
by Section 2(a) of the Registration Rights Agreement is first declared
effective by the Commission.

      "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended.

      "GAAP" means U.S. generally accepted accounting principles.

      "INTELLECTUAL PROPERTY RIGHTS" has the meaning set forth in
Section 3(a)(xiv).

      "INVESTOR DELIVERABLES" has the meaning set forth in Section 2(b)(ii).

      "INVESTOR PARTY" has the meaning set forth in Section 4(f).

      "LICENSE AGREEMENT" means the Patent and Technology License Agreement,
dated as of the date hereof, among the Company and the Investor, in the form
attached hereto as Exhibit A.

      "LIEN" means any lien, charge, encumbrance, security interest, right of
first refusal or other restrictions of any kind.

      "MATERIAL ADVERSE EFFECT" means any of (i) a material and adverse effect
on the legality, validity or enforceability of any Transaction Document, (ii) a
material and adverse effect on the results of operations, assets, business,
condition (financial or otherwise) or prospects of the Company and the
Subsidiaries, taken as a whole, or (iii) an adverse impairment to the Company's
ability to perform on a timely basis its obligations under any Transaction
Document.

      "PERMISSIBLE TRANSFEREE" means RSM Ventures, a limited liability company,
together with its Affiliates.

      "PERSON" means an individual or corporation, partnership, trust,
incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof)
or other entity of any kind.

      "PROCEEDING" means an action, claim, suit, investigation or proceeding
(including, without limitation, an investigation or partial proceeding, such as
a deposition), whether commenced or threatened.

      "REGISTRATION STATEMENT" means a registration statement meeting the
requirements set forth in the Registration Rights Agreement and covering the
resale by the Investor of the Shares and the Warrant Shares.

      "REGISTRATION RIGHTS AGREEMENT" means the Registration Rights Agreement,
dated as of the date of this Agreement, among the Company and the Investor, in
the form of Exhibit B hereto.

                                       2
<PAGE>

      "RULE 144" means Rule 144 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar
rule or regulation hereafter adopted by the Commission having substantially the
same effect as such Rule.

      "SALE LIMITATION AMOUNT" means in any trading day, excluding block trades
and similar transactions, not more than twenty-five percent (25%) of the
average daily trading volume of the Common Stock during the five (5) trading
days immediately preceding the calendar week in which the Shares are sold.

      "SEC REPORTS" has the meaning set forth in Section 3(a)(viii).

      "SECURITIES" means the Shares, the Warrants and the Warrant Shares.

      "SECURITIES ACT" means the Securities Act of 1933, as amended.

      "SHARES" means the shares of Common Stock issued to the Investor pursuant
to the terms and provisions of this Agreement, including, without limitation,
any shares of Common Stock purchased by the Investor pursuant to Section
4(a)(v) hereof.

      "SUBSIDIARY" of any Person means another Person, an amount of the voting
securities, other voting ownership or voting partnership interests of which is
sufficient to elect at least a majority of its Board of Directors or other
governing body (or, if there are no such voting interests, 50% or more of the
equity interests of which is owned directly or indirectly by such first
person).

      "TERM SHEET" means that certain letter agreement between PointSource
Technologies, LLC and JMAR Technologies, Inc. dated January 7, 2005.

      "TRADING DAY" means (i) a day on which the Common Stock is traded on a
Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock
is not listed on a Trading Market (other than the OTC Bulletin Board), a day on
which the Common Stock is traded in the over-the-counter market, as reported by
the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any
Trading Market, a day on which the Common Stock is quoted in the over-the-
counter market as reported by the National Quotation Bureau Incorporated (or
any similar organization or agency succeeding to its functions of reporting
prices); provided, that in the event that the Common Stock is not listed or
quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean
a Business Day.

      "TRADING MARKET" means whichever of the New York Stock Exchange, the
American Stock Exchange, the NASDAQ National Market, the NASDAQ SmallCap Market
or OTC Bulletin Board on which the Common Stock is listed or quoted for trading
on the date in question.

      "TRANSACTION DOCUMENTS" means this Agreement, the Registration Rights
Agreement, the Warrants and any other documents or agreements executed in
connection with the transactions contemplated hereunder.

                                       3
<PAGE>

      "WARRANT SHARES" means the shares of Common Stock issuable upon exercise
of the Warrants.

      "WARRANTS" means the warrants to purchase Common Stock issued or issuable
to the Investor pursuant to this Agreement in the form attached hereto as
Exhibit C.

      2.    Purchase and Sale

            (a)   Closing.  On or before the Closing consummated pursuant to
this Agreement, subject to the terms and conditions set forth in this
Agreement, the Company shall issue to the Investor, (i) Five Hundred Twenty
Thousand (520,000) shares of Common Stock and (ii) a Warrant to purchase Three
Hundred Thirty Three Thousand Three Hundred Thirty Three (333,3333) shares of
Common Stock.  The closing of the transactions contemplated by this Agreement
(the "CLOSING") shall take place at the offices of Morrison & Foerster, 3811
Valley Centre Drive, Suite 500, San Diego, California 92130 on January 25, 2005
or at such other location or time as the parties to the Closing may agree.

            (b)   Closing Deliveries.

                  (i)   At the Closing, the Company shall deliver or cause to
be delivered to the Investor the following (the "COMPANY DELIVERABLES"):

                        (1)   a certificate evidencing Five Hundred Twenty
Thousand (520,000) shares of Common Stock, registered in the name of Investor
or its nominee;

                        (2)   a Warrant to purchase Three Hundred Thirty Three
Thousand Three Hundred Thirty Three (333,333) shares of Common Stock;

                        (3)   the legal opinion of Company Counsel, in agreed
form, addressed to the Investor;

                        (4)   the Registration Rights Agreement, duly executed
by the Company;

                        (5)   a Certificate, executed on behalf of the Company
by its Chief Executive Officer or its Chief Financial Officer, dated as of the
Closing, certifying to the fulfillment of the conditions specified in
Section 5(a); and

                        (6)   a Certificate, executed on behalf of the Company
by its Secretary, dated as of the Closing, certifying the resolutions adopted
by the Board of Directors of the Company approving the transactions
contemplated by this Agreement and the other Transaction Documents and the
issuance of the Securities, certifying the current versions of the Certificate
of Incorporation and Bylaws of the Company and certifying as to the signatures
and authority of persons signing the Transaction Documents and related
documents on behalf of the Company.

                  (ii)  At the Closing, the Investor shall deliver or cause to
be delivered to the Company the following (the "INVESTOR DELIVERABLES"):

                                       4
<PAGE>

                        (1)   the Registration Rights Agreement, duly executed
by the Investor;

                        (2)   the License Agreement, duly executed by the
Investor; and

                        (3)   the Bill of Sale, in substantially the form
attached hereto as Exhibit D, duly executed by the Investor.

      3.    Representations and Warranties

            (a)   Representations and Warranties of the Company.  The Company
hereby makes the following representations and warranties to the Investor:

                  (i)   Subsidiaries.  Except for those Subsidiaries which are
not conducting any operations nor have any materials assets, the Company has no
direct or indirect Subsidiaries other than as specified in the SEC Reports.
Except as specified on Schedule 3(a)(xiii), the Company owns, directly or
indirectly, all of the capital stock of each Subsidiary free and clear of any
and all Liens, and all the issued and outstanding shares of capital stock of
each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights.  Neither the Company nor any Subsidiary is
party to any material joint venture, nor has any ownership interest in any
other entity that is material to the Company or as disclosed in the SEC
Reports.

                  (ii)  Organization and Qualification.  The Company and each
Subsidiary are duly incorporated or otherwise organized, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or
organization (as applicable), with the requisite power and authority to own and
use its properties and assets and to carry on its business as currently
conducted.  Neither the Company nor any Subsidiary is in violation of any of
the material provisions of its respective certificate or articles of
incorporation, bylaws or other organizational or charter documents.  The
Company and each Subsidiary are duly qualified to conduct its respective
businesses and are in good standing as a foreign corporation or other entity in
each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be
so qualified or in good standing, as the case may be, could not, individually
or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect.

                  (iii) Authorization; Enforcement.  The Company has the
requisite power and authority and has taken all requisite action on the part of
the Company, its officers, directors and stockholders necessary for (i) the
authorization, execution and delivery of the Transaction Documents, (ii) the
authorization of the performance of all obligations of the Company hereunder or
thereunder, and (iii) the authorization, issuance (or reservation for issuance)
and delivery of the Securities.  Each Transaction Document has been (or upon
delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with
its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws

                                       5
<PAGE>

relating to, or affecting generally the enforcement of, creditors' rights and
remedies or by other equitable principles of general application.

                  (iv)  No Conflicts.  The execution, delivery and performance
of the Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated thereby do not and will not (i) conflict with
or violate any provision of the Company's or any Subsidiary's certificate or
articles of incorporation, bylaws or other organizational or charter documents,
or (ii) conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any agreement, credit facility, debt or
other instrument (evidencing a Company or Subsidiary debt or otherwise) to
which the Company or any Subsidiary is a party or by which any property or
asset of the Company or any Subsidiary is bound, or (iii) result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company or a
Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii) and (iii),
such as could not, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect.

                  (v)   Filings, Consents and Approvals.  The Company is not
required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal,
state, local or other governmental authority or other Person in connection with
the execution, delivery and performance by the Company of the Transaction
Documents and the offer, issuance and sale of the Securities, other than
(i) the filing with the Commission of one or more Registration Statements in
accordance with the requirements of the Registration Rights Agreement,
(ii) filings required by state securities laws, (iii) the filing of a Notice of
Sale of Securities on Form D with the Commission under Regulation D of the
Securities Act, (iv) the filings required in accordance with Section 4(d),
(v) the filing of any requisite notices with the Trading Market, (vi) such
consents or waivers as may be required under registration rights agreements
entered into in connection with business acquisitions effected prior to the
date of this Agreement, and (vii) those that have been made or obtained prior
to the date of this Agreement.  Subject to the accuracy of the representations
and warranties of the Investor set forth in Section 3(b) hereof, the Company
has taken all action necessary to exempt (i) the issuance and sale of the
Securities, (ii) the issuance of the Warrant Shares upon due exercise of the
Warrants, and (iii) the other transactions contemplated by the Transaction
Documents from the provisions of any shareholder rights plan or other "poison
pill" arrangement, or any anti-takeover, business combination or control share
law or statute binding on the Company or to which the Company or any of its
assets and properties may be subject and any provisions of the Company's
Certificate of Incorporation or Bylaws that is or could reasonably be expected
to become applicable to the Investor as a result of the transactions
contemplated hereby, including without limitation, the issuance of the
Securities and the ownership, disposition or voting of the Securities by the
Investor or the exercise of any right granted to the Investor pursuant to this
Agreement or the other Transaction Documents.

                  (vi)  Issuance of the Securities.  The Securities have been
duly authorized and, when issued in accordance with the Transaction Documents,
will be duly and

                                       6
<PAGE>

validly issued, fully paid and nonassessable, free and clear of all Liens. The
Company has reserved from its duly authorized capital stock the shares of Common
Stock issuable pursuant to this Agreement in order to issue the Shares and the
Warrant Shares.

                  (vii) Capitalization.  The number of shares and type of all
authorized, issued and outstanding capital stock of the Company, and all shares
of Common Stock reserved for issuance under the Company's various option and
incentive plans as of December 31, 2003, is specified in the SEC Reports.
Except as specified on Schedule 3(a)(vii) and in the SEC Reports, no securities
of the Company are entitled to preemptive or similar rights, and no Person has
any right of first refusal, preemptive right, right of participation, or any
similar right to participate in the transactions contemplated by the
Transaction Documents.

                  (viii)SEC Reports; Financial Statements.  The Company has
filed all reports required to be filed by it under the Securities Act and the
Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
twelve months preceding the date hereof (or such shorter period as the Company
was required by law to file such reports) (the foregoing materials being
collectively referred to herein as the "SEC REPORTS" and, together with the
Schedules to this Agreement (if any), the "DISCLOSURE MATERIALS") on a timely
basis or has timely filed a valid extension of such time of filing and has
filed any such SEC Reports prior to the expiration of any such extension.  As
of their respective dates, the SEC Reports complied in all material respects
with the requirements of the Securities Act and the Exchange Act and the rules
and regulations of the Commission promulgated thereunder, and none of the SEC
Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading.  The financial statements of the Company
included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with
respect thereto as in effect at the time of filing.  Such financial statements
have been prepared in accordance with GAAP applied on a consistent basis during
the periods involved, except as may be otherwise specified in such financial
statements or the notes thereto, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of
and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal
year-end audit adjustments.

                  (ix)  Material Changes.  Except as specified on
Schedule 3(a)(ix), since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in the SEC
Reports, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise)
other than (A) trade payables, accrued expenses and other liabilities incurred
in the ordinary course of business consistent with past practice and
(B) liabilities not required to be reflected in the Company's financial
statements pursuant to GAAP or required to be disclosed in filings made with
the Commission, (iii) the Company has not altered its method of accounting or
the identity of its auditors, (iv) the Company has not declared or made any
dividend or distribution of cash or other property to its stockholders or
purchased, redeemed or made any agreements to purchase or redeem any shares of
its capital stock (other than in connection with repurchases of unvested stock
issued to

                                       7
<PAGE>

employees of the Company), and (v) the Company has not issued any equity
securities to any officer, director or Affiliate, except pursuant to existing
Company stock option plans.

                  (x)   Litigation.  There is no Action which (i) adversely
affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) except as specifically
disclosed in the SEC Reports, could, if there were an unfavorable decision,
individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect.  Neither the Company nor any Subsidiary, nor any
director or officer thereof (in his or her capacity as such), is or has been
the subject of any Action involving a claim of violation of or liability under
federal or state securities laws or a claim of breach of fiduciary duty, except
as specifically disclosed in the SEC Reports.  There has not been, and to the
knowledge of the Company, there is not pending any investigation by the
Commission involving the Company or any current or former director or officer
of the Company (in his or her capacity as such).  The Commission has not issued
any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.

                  (xi)  Compliance.  Neither the Company nor any Subsidiary
(i) is in default under or in violation of (and no event has occurred that has
not been waived that, with notice or lapse of time or both, would result in a
default by the Company or any Subsidiary under), nor has the Company or any
Subsidiary received notice of a claim that it is in default under or that it is
in violation of, any indenture, loan or credit agreement or any other agreement
or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in
violation of, or in receipt of notice that it is in violation of, any order of
any court, arbitrator or governmental body, or (iii) is or has been in
violation of, or in receipt of notice that it is in violation of, any statute,
rule or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety,
employment and labor matters and, to its knowledge, privacy, except in each
case as could not, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect.

                  (xii) Regulatory Permits.  The Company and the Subsidiaries
possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct
their respective businesses as described in the SEC Reports, except where the
failure to possess such permits could not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect, and
neither the Company nor any Subsidiary has received any notice of proceedings
relating to the revocation or modification of any such permits.

                  (xiii)Title to Assets.  Except as described in the SEC
Reports or as specified on Schedule 3(a)(xiii), the Company and the
Subsidiaries have good and marketable title in fee simple to all real property
owned by them that is material to their respective businesses and good and
marketable title in all personal property owned by them that is material to
their respective businesses, in each case free and clear of all Liens, except
for Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property
by the Company and the Subsidiaries. Any real property

                                       8
<PAGE>

and facilities held under lease by the Company and the Subsidiaries are held by
them under leases valid, subsisting and enforceable against the Company and the
Subsidiaries, and the Company and the Subsidiaries are in compliance with such
leases, except as could not, individually or in the aggregate, have or
reasonably be expected to result in a Material Adverse Effect.

                  (xiv) Labor Matters.  No material labor dispute with the
employees of the Company or any Subsidiary exists or, to the Company's
knowledge, is imminent.

                  (xv)  Intellectual Property.

                        (1)   All Intellectual Property of the Company and its
Subsidiaries is currently in compliance with all legal requirements (including
timely filings, proofs and payments of fees) and is valid and enforceable.  No
Intellectual Property of the Company or its Subsidiaries which is necessary for
the conduct of Company's and each of its Subsidiaries' respective businesses as
currently conducted or as currently proposed to be conducted has been or is now
involved in any cancellation, dispute or litigation, and, to the Company's
knowledge, no such action is threatened.  No patent of the Company or its
Subsidiaries has been or is now involved in any interference, reissue, re-
examination or opposition proceeding.

                        (2)   All of the licenses and sublicenses and consent,
royalty or other agreements concerning Intellectual Property which are
necessary for the conduct of the Company's and each of its Subsidiaries'
respective businesses as currently conducted or as currently proposed to be
conducted to which the Company or any Subsidiary is a party or by which any of
their assets are bound (other than  generally commercially available,
non-custom, off-the-shelf software application programs having a retail
acquisition price of less than $10,000 per license) (collectively, "License
Agreements") are valid and binding obligations of the Company or its
Subsidiaries that are parties thereto and, to the Company's knowledge, the
other parties thereto, enforceable in accordance with their terms, except to
the extent that enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance or other similar laws
affecting the enforcement of creditors' rights generally, and there exists no
event or condition which will result in a material violation or breach of or
constitute (with or without due notice or lapse of time or both) a default by
the Company or any of its Subsidiaries under any such License Agreement.

                        (3)   The Company and its Subsidiaries own or have the
valid right to use all of the Intellectual Property that is necessary for the
conduct of the Company's and each of its Subsidiaries' respective businesses as
currently conducted or as currently proposed to be conducted and for the
ownership, maintenance and operation of the Company's and its Subsidiaries'
properties and assets, free and clear of all liens, encumbrances, adverse
claims or obligations to license all such owned Intellectual Property and
Confidential Information, other than licenses entered into in the ordinary
course of the Company's and its Subsidiaries' businesses.  The Company and its
Subsidiaries have a valid and enforceable right to use all third party
Intellectual Property and Confidential Information used or held for use in the
respective businesses of the Company and its Subsidiaries.

                                       9
<PAGE>

                        (4)   To the Company's knowledge, the conduct of the
Company's and its Subsidiaries' businesses as currently conducted does not
infringe or otherwise impair or conflict with (collectively, "Infringe") any
Intellectual Property rights of any third party or any confidentiality
obligation owed to a third party, and, to the Company's knowledge, the
Intellectual Property and Confidential Information of the Company and its
Subsidiaries which are necessary for the conduct of Company's and each of its
Subsidiaries' respective businesses as currently conducted or as currently
proposed to be conducted are not being Infringed by any third party.  There is
no litigation or order pending or outstanding or, to the Company's knowledge,
threatened or imminent, that seeks to limit or challenge or that concerns the
ownership, use, validity or enforceability of any Intellectual Property or
Confidential Information of the Company and its Subsidiaries and the Company's
and its Subsidiaries' use of any Intellectual Property or Confidential
Information owned by a third party, and, to the Company's knowledge, there is
no valid basis for the same.

                        (5)   The consummation of the transactions contemplated
hereby and by the other Transaction Documents will not result in the
alteration, loss, impairment of or restriction on the Company's or any of its
Subsidiaries' ownership or right to use any of the Intellectual Property or
Confidential Information which is necessary for the conduct of Company's and
each of its Subsidiaries' respective businesses as currently conducted or as
currently proposed to be conducted.

                        (6)   The Company has not used any algorithms developed
by William Fitzgerald other than what was already in the public domain through
no fault of Gregory Quist, David Drake or the LXT Group prior to their use.

                        (7)   The Company has not used any information covered
by any claims in any unexpired patents issued to Wyatt Technology Corporation.

                  (xvi) Insurance.  The Company and the Subsidiaries are
insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary for enterprises of
similar size and stage of development in the businesses in which the Company
and the Subsidiaries are engaged.  The Company has no reason to believe that it
will not be able to renew its and the Subsidiaries' existing insurance coverage
as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business on terms consistent with
market for the Company's and such Subsidiaries' respective lines of business.

                  (xvii)Environmental Matters.  Neither the Company nor any
Subsidiary is in violation of any statute, rule, regulation, decision or order
of any governmental agency or body or any court, domestic or foreign, relating
to the use, disposal or release of hazardous or toxic substances or relating to
the protection or restoration of the environment or human exposure to hazardous
or toxic substances (collectively, "ENVIRONMENTAL LAWS"), owns or operates any
real property contaminated with any substance that is subject to any
Environmental Laws, is liable for any off-site disposal or contamination
pursuant to any Environmental Laws, and is subject to any claim relating to any
Environmental Laws, which violation, contamination, liability or claim has had
or could reasonably be expected to have a Material Adverse Effect,

                                       10
<PAGE>

individually or in the aggregate; and there is no pending or, to the Company's
knowledge, threatened investigation that might lead to such a claim.

                  (xviii)Transactions With Affiliates and Employees.  Except as
set forth in the SEC Reports, none of the officers or directors of the Company
and, to the knowledge of the Company, none of the employees of the Company is
presently a party to any transaction with the Company or any Subsidiary
required to be disclosed in the SEC Reports (other than for services as
employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for
rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the
Company, any entity in which any officer, director, or any such employee has a
substantial interest or is an officer, director, trustee or partner.

                  (xix) Internal Accounting Controls.  The Company has
established disclosure controls and procedures (as defined in Exchange Act
rules 13a-14 and 15d-14) for the Company and designed such disclosure controls
and procedures to ensure that material information relating to the Company,
including its Subsidiaries, is made known to the certifying officers by others
within those entities.  The Company's certifying officers have evaluated the
effectiveness of the Company's disclosure controls and procedures in accordance
with Regulation S-K under the Exchange Act for the fiscal quarter ended
September 30, 2004 (such date, the "EVALUATION DATE").  The Company presented
in its most recently filed Form 10-Q the conclusions of the certifying officers
about the effectiveness of the disclosure controls and procedures based on
their evaluations as of the Evaluation Date.  Since the Evaluation Date, there
have been no significant changes in the Company's internal controls (as such
term is defined in Regulation S-K under the Exchange Act) or, to the Company's
knowledge, in other factors that could significantly affect the Company's
internal controls which was required to be disclosed in the SEC Reports and was
not so disclosed.

                  (xx)  Certain Fees.  The Investor shall have no obligation
with respect to any fees or with respect to any claims (other than such fees or
commissions owed the Investor pursuant to written agreements executed by the
Investor which fees or commissions shall be the sole responsibility of the
Investor) made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions
contemplated by this Agreement.

                  (xxi) Investment Company.  The Company is not, and is not an
Affiliate of, and immediately following the Closing will not have become, an
"investment company" within the meaning of the Investment Company Act of 1940,
as amended.

                  (xxii)Certain Registration Matters.  Assuming the accuracy of
the Investor's representations and warranties set forth in Section 3(b)(ii)-
(v), no registration under the Securities Act is required for the offer and
sale of the Securities by the Company to the Investor under the Transaction
Documents.  Neither the Company nor any Person acting on its behalf has
conducted any general solicitation or general advertising (as those terms are
used in Regulation D promulgated under the Securities Act) in connection with
the offer or sale of any of the Securities.  Neither the Company nor any of its
Affiliates, nor any Person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any Company security or

                                       11
<PAGE>

solicited any offers to buy any security, under circumstances that would
adversely affect reliance by the Company on Section 4(2) of the Securities Act
for the exemption from registration for the transaction contemplated hereby or
would require registration of the Securities under the Securities Act. Except as
specified on Schedule 3(a)(xxii) and pursuant to the Registration Rights
Agreement, the Company has not granted or agreed to grant to any Person any
rights (including "piggy-back" registration rights) to have any securities of
the Company registered with the Commission or any other governmental authority
that have not been satisfied.

                  (xxiii) Listing and Maintenance Requirements.  Except as
specified in the SEC Reports and except in connection with its transition in
May, 2003 from the NASDAQ National Market System to the NASDAQ Small Cap, the
Company has not, in the two years preceding the date hereof, received notice
from any Trading Market to the effect that the Company is not in compliance
with the listing or maintenance requirements thereof.  Subject to the
successful completion of the financing and amendments described on Schedules
3(a)(ix), the Company is, and has no reason to believe that it will not in the
foreseeable future continue to be, in compliance with the listing and
maintenance requirements for continued listing of the Common Stock on the
Trading Market on which the Common Stock is currently listed or quoted.  The
issuance and sale of the Securities under the Transaction Documents does not
contravene the rules and regulations of the Trading Market on which the Common
Stock is currently listed or quoted, and no approval of the shareholders of the
Company thereunder is required for the Company to issue and deliver to the
Investor the Securities contemplated by Transaction Documents.

                  (xxiv) No Additional Agreements.  The Company does not have
any agreement or understanding with the Investor with respect to the
transactions contemplated by the Transaction Documents other than as specified
in the Transaction Documents.

                  (xxv) Disclosure.  Neither the Company nor any Person acting
on its behalf has provided the Investor or its agents or counsel with any
information that constitutes or might constitute material, non-public
information.  The Company understands and confirms that the Investor will rely
on the foregoing representations and covenants in effecting transactions in
securities of the Company.  All disclosure provided to the Investor regarding
the Company, its business and the transactions contemplated hereby, furnished
by or on behalf of the Company (including the Company's representations and
warranties set forth in this Agreement) are true and correct and do not contain
any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading.

            (b)   Representations and Warranties of the Investor.  The Investor
hereby represents and warrants to the Company as follows:

                  (i)   Organization; Authority.  The Investor is an entity
duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization with the requisite corporate, partnership or
limited liability company power and authority to enter into and to consummate
the transactions contemplated by the applicable Transaction Documents and
otherwise to carry out its obligations thereunder. The execution, delivery and
performance by the Investor of the transactions contemplated by this Agreement
has been duly authorized by all

                                       12
<PAGE>

necessary corporate or, if the Investor is not a corporation, such partnership,
limited liability Company or other applicable like action, on the part of the
Investor. Each of this Agreement and the Registration Rights Agreement has been
duly executed by the Investor, and when delivered by the Investor in accordance
with terms hereof, will constitute the valid and legally binding obligation of
the Investor, enforceable against it in accordance with its terms, except as
such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally the enforcement of, creditors' rights and remedies or by
other equitable principles of general application.

                  (ii)  Investment Intent.  The Investor is acquiring the
Securities as principal for its own account for investment purposes only and
not with a view to or for distributing or reselling such Securities or any part
thereof, without prejudice, however, to the Investor's right at all times to
sell or otherwise dispose of all or any part of such Securities in compliance
with applicable federal and state securities laws.  Subject to the immediately
preceding sentence, nothing contained herein shall be deemed a representation
or warranty by the Investor to hold the Securities for any period of time.  The
Investor is acquiring the Securities hereunder in the ordinary course of its
business.  The Investor does not have any agreement or understanding, directly
or indirectly, with any Person to distribute any of the Securities other than
to a Permissible Transferee.  Notwithstanding the foregoing, it is hereby
acknowledged by all parties that the Investor may transfer the Securities to a
Permissible Transferee.

                  (iii) Investor Status.  The Investor is, and at the Closing
will be, an "accredited investor" as defined in Rule 501(a) under the
Securities Act.

                  (iv)  General Solicitation.  The Investor is not purchasing
the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or
similar media or broadcast over television or radio or presented at any seminar
or any other general solicitation or general advertisement.

                  (v)   Access to Information.  The Investor acknowledges that
it has reviewed the Disclosure Materials and has been afforded (i) the
opportunity to ask such questions as it has deemed necessary of, and to receive
answers from, representatives of the Company concerning the terms and
conditions of the offering of the Securities and the merits and risks of
investing in the Securities; (ii) access to information about the Company and
the Subsidiaries and their respective capital structures, financial condition,
results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to the investment.  Neither such inquiries nor
any other investigation conducted by or on behalf of the Investor or its
representatives or counsel shall modify, amend or affect the Investor's right
to rely on the truth, accuracy and completeness of the Disclosure Materials and
the Company's representations and warranties contained in the Transaction
Documents.

                  (vi)  Independent Investment Decision.  The Investor has
independently evaluated the merits of its decision to acquire Securities
pursuant to the Transaction Documents,

                                       13
<PAGE>

and the Investor confirms that it has not relied on the advice of any other
Investor's business and/or legal counsel in making such decision.

The Company acknowledges and agrees that the Investor has not made or does not
make any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in this
Section 3(b).

      4.    Other Agreements of the Parties

            (a)   Sale of Securities.

                  (i)   Compliance with Laws; Permissible Transfers.  The
Securities may only be disposed of in compliance with state and federal
securities laws.  In connection with any transfer of the Securities other than
pursuant to an effective registration statement, pursuant to Rule 144(k), to
the Company, to an Affiliate of the Investor, to a Permissible Transferee or in
connection with a pledge as contemplated in Section 4(a)(ii), the Company may
require the transferor thereof to provide to the Company an opinion of counsel
selected by the transferor, the form and substance of which opinion shall be
reasonably satisfactory to the Company, to the effect that such transfer does
not require registration of such transferred Securities under the Securities
Act.  Notwithstanding the foregoing, Investor may assign or transfer all or any
portion of the Securities to a Permissible Transferee.

                  (ii)  Legends.  Certificates evidencing the Securities will
contain a  legend substantially similar to the following, until such time as
they are not required under Section 4(a)(iii):

            THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES
            AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
            STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
            THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
            ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT
            PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
            SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
            IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
            REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
            APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
            OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
            SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
            COMPANY OR UNLESS SOLD IN FULL COMPLIANCE WITH RULE 144 UNDER
            THE SECURITIES ACT.  THESE SECURITIES MAY BE PLEDGED IN
            CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH
            SECURITIES.

                                       14
<PAGE>

      The Company acknowledges and agrees that the Investor may from time to
time pledge, and/or grant a security interest in some or all of the Securities
pursuant to a bona fide margin agreement in connection with a bona fide margin
account and, if required under the terms of such agreement or account, the
Investor may transfer pledged or secured Securities to the pledgees or secured
parties.  Such a pledge or transfer would not be subject to approval or consent
of the Company and no legal opinion of legal counsel to the pledgee, secured
party or pledgor shall be required in connection with the pledge, but such
legal opinion may be required in connection with a subsequent transfer
following default by the Investor transferee of the pledge.  No notice shall be
required of such pledge.  At the Investor's expense, the Company will execute
and deliver such reasonable documentation as a pledgee or secured party of
Securities may reasonably request in connection with a pledge or transfer of
the Securities including the preparation and filing of any required prospectus
supplement under Rule 424(b)(3) of the Securities Act or other applicable
provision of the Securities Act to appropriately amend the list of Selling
Stockholders thereunder.

                  (iii) Sales/Transfers Pursuant to Registration Statement or
Rule 144.  Certificates evidencing the Shares and the Warrant Shares shall not
contain any legend (including the legend set forth in Section 4(a)(ii)):
(i) following a sale or transfer of such Securities pursuant to an effective
registration statement (including the Registration Statement), or
(ii) following a sale or transfer of such Shares and Warrant Shares pursuant to
Rule 144 (assuming the transferor is not an Affiliate of the Company), or
(iii) while such Shares and Warrant Shares are eligible for sale under
Rule 144(k).  The Company may not make any notation on its records or give
instructions to any transfer agent of the Company that enlarge the restrictions
on transfer set forth in this Section.

                  (iv)  Sales Limitations.  The Investor agrees during the
Effectiveness Period (as such term is defined in the Registration Rights
Agreement) to limit the number of shares of Common Stock sold by such Investor
in the public market in any trading day to the Sale Limitation Amount.

                  (v)   Subsequent Purchase Right.  Subject to the terms and
conditions specified in this Section 4(a)(v), the Company hereby grants to the
Investor a purchase right with respect to future sales by the Company of its
Equity Securities (as defined below).  For purposes of this Section 4(a)(v),
Investor includes any general partners and affiliates of the Investor.  The
Investor shall be entitled to apportion the subsequent purchase right hereby
granted it among itself and its partners and affiliates in such proportions as
it deems appropriate, so long as such apportionment does not cause the loss of
the exemption under Section 4(2) of the Act or any similar exemption under
applicable state securities laws in connection with such sale of Equity
Securities by the Company.  The Investor will be entitled to the subsequent
purchase right from the Closing Date to the earlier of (i) eighteen (18) months
after the Closing Date, and (ii) the date that the total number of Shares held
by the Investor falls below 100,000 shares (as adjusted for stock splits,
dividends, recapitalizations and the like).

      Following the Closing Date, in the event that the Company completes the
issuance of any shares of, or securities convertible into or exchangeable or
exercisable for any shares of, any class of its capital stock (the "EQUITY
SECURITIES"), the Company shall subsequently make an offering of such Equity
Securities to the Investor in accordance with the following provisions:

                                       15
<PAGE>

                       (1)   Within five (5) days following the issuance of
any Equity Securities, the Company shall deliver a notice in accordance with
Section 6(c) (the "NOTICE") to the Investor stating (i) the number of such
Equity Securities issued and (ii) the price and terms upon which it issued such
Equity Securities.

                        (2)   By written notification received by the Company,
within twenty (20) calendar days after receipt of the Notice, the Investor may
elect to purchase or obtain, at the price and on the terms specified in the
Notice, up to that portion of such Equity Securities that equals the product of
(i) the number of Equity Securities sold, multiplied by (ii) the number of
Shares (including any shares of common stock then held by Investor that were
issued upon exercise of the Warrants, but excluding any Warrant Shares issuable
but not yet issued under the Warrant) then held by the Investor divided by the
total number of shares of the Company's common stock outstanding on the date of
the Term Sheet.

                        (3)   The subsequent purchase right in this
Section 4(a)(v) shall not be applicable to any issuances of the Company's
Equity Securities, options or warrants in connection with:

                              (A)   the Company's stock option plans or
employee benefit plans in effect on the Closing Date;

                              (B)   the exercise or conversion of options,
warrants or convertible securities that are outstanding on the Effective Date;

                              (C)   acquisitions or other transactions of the
Company involving payment other than with cash;

                              (D)   the Company's outstanding receivables-based
$3 million Revolving Convertible Note issued to Laurus Master Fund, the
outstanding balance of which changes from time-to-time; or

                              (E)   any Shares issued pursuant to this Section
4(a)(v).

                        (4)   Investor shall complete its purchase of the
Shares no later than fifteen (15) days after delivery of its notice of election
to purchase.

      The subsequent purchase right set forth in this Section 4(a)(v) may not
be assigned or transferred, except that such right is assignable by the
Investor to (i) any wholly-owned subsidiary or parent of, or to any corporation
or entity that is, within the meaning of the Act, controlling, controlled by or
under common control with, the Investor, and (ii) a Permissible Transferee.

            (b)   Furnishing of Information.  As long as the Investor owns the
Securities, the Company covenants to timely file (or obtain extensions in
respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof

                                       16
<PAGE>

pursuant to the Exchange Act. As long as the Investor owns Securities, if the
Company is not required to file reports pursuant to such laws, it will prepare
and furnish to the Investor and make publicly available in accordance with Rule
144(c) such information as is required for the Investor to sell the Shares under
Rule 144. The Company further covenants that it will take such further action as
any holder of Securities may reasonably request, all to the extent required from
time to time to enable such Person to sell the Shares without registration under
the Securities Act within the limitation of the exemptions provided by Rule 144.

            (c)   Integration.  The Company shall not, and shall use its best
efforts to ensure that no Affiliate of the Company shall, sell, offer for sale
or solicit offers to buy or otherwise negotiate in respect of any security (as
defined in Section 2 of the Securities Act) that would be integrated with the
offer or sale of the Securities in a manner that would require the registration
under the Securities Act of the sale of the Securities to the Investor, or that
would be integrated with the offer or sale of the Securities for purposes of
the rules and regulations of any Trading Market in a manner that would require
stockholder approval of the sale of the securities to the Investor.

            (d)   Securities Laws Disclosure; Publicity.  By no later than
9:00 a.m. (New York time) on the fourth Trading Day following the execution of
this Agreement, and by no later than 9:00 a.m. (New York time) on the fourth
Trading Day following the Closing Date, the Company shall issue press releases
disclosing the transactions contemplated hereby and the Closing.  By no later
than the fourth Trading Day following the execution of this Agreement, the
Company will file a Current Report on Form 8-K disclosing the material terms of
the Transaction Documents, and on no later than the fourth Trading Day after
the Closing Date the Company will file an additional Current Report on Form 8-K
to disclose the Closing.  In addition, the Company will make such other filings
and notices in the manner and time required by the Commission and the Trading
Market on which the Common Stock is listed.

            (e)   Limitation on Issuance of Future Priced Securities.  During
the six months following the Closing Date, the Company shall not issue any
"Future Priced Securities" as such term is described by NASD IM-4350-1.

            (f)   Indemnification of Investor.  In addition to the indemnity
provided in the Registration Rights Agreement, the Company will indemnify and
hold the Investor and its directors, officers, shareholders, partners,
employees, affiliates and agents (each, an "INVESTOR PARTY") harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs
and expenses, including all judgments, amounts paid in settlements, court costs
and reasonable attorneys' fees and costs of investigation (collectively,
"LOSSES") that the Investor Party may suffer or incur as a result of or
relating to any misrepresentation, breach or inaccuracy of any representation,
warranty, covenant or agreement made by the Company in any Transaction
Document.  In addition to the indemnity contained herein, the Company will
reimburse the Investor Party for its reasonable legal and other expenses
(including the cost of any investigation, preparation and travel in connection
therewith) incurred in connection therewith, as such expenses are incurred.

            (g)   Non-Public Information.  The Company covenants and agrees
that neither it nor any other Person acting on its behalf will provide the
Investor or its agents or counsel with

                                       17
<PAGE>

any information that the Company believes constitutes material non-public
information, unless prior thereto the Investor shall have executed a written
agreement regarding the confidentiality and use of such information. The Company
understands and confirms that the Investor shall be relying on the foregoing
representations in effecting transactions in securities of the Company.

            (h)   Listing of Securities.  The Company agrees, (i) if the
Company applies to have the Common Stock traded on any other Trading Market, it
will include in such application the Shares and the Warrant Shares, and will
take such other action as is necessary or desirable to cause the Shares and the
Warrant Shares to be listed on such other Trading Market as promptly as
possible, and (ii) it will take all action reasonably necessary to continue the
listing and trading of its Common Stock on a Trading Market and will comply in
all material respects with the Company's reporting, filing and other
obligations under the bylaws or rules of the Trading Market.

      5.    Conditions Precedent to Closing

            (a)   Conditions Precedent to the Obligations of the Investor to
Acquire Securities.  The obligation of the Investor to acquire Securities at a
Closing is subject to the satisfaction or waiver by the Investor, at or before
the Closing, of each of the following conditions:

                  (i)   Representations and Warranties.  The representations
and warranties of the Company contained herein shall be true and correct in all
material respects as of the date when made and as of the Closing as though made
on and as of such date, except that representations and warranties that are
qualified by materiality shall be true and correct as of the date when made and
as of the Closing as though made on and as of such date;

                  (ii)  Performance.  The Company shall have performed,
satisfied and complied in all material respects with all covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied
or complied with by it at or prior to the Closing;

                  (iii) No Injunction.  No statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent
jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents;

                  (iv)  Adverse Changes.  Since the date of execution of this
Agreement, no event or series of events shall have occurred that reasonably
could have or result in a Material Adverse Effect;

                  (v)   No Suspensions of Trading in Common Stock; Listing.
Trading in the Common Stock shall not have been suspended by the Commission or
any Trading Market (except for any suspensions of trading of not more than one
Trading Day solely to permit dissemination of material information regarding
the Company) at any time since the date of execution of this Agreement, and the
Common Stock shall have been at all times since such date listed for trading
(or quoted) on a Trading Market; and

                                       18
<PAGE>

                  (vi)  Company Deliverables.  The Company shall have delivered
the Company Deliverables in accordance with Section 2(b)(i).

            (b)   Conditions Precedent to the Obligations of the Company to
Sell Securities.  The obligation of the Company to sell Securities at a Closing
is subject to the satisfaction or waiver by the Company, at or before the
Closing, of each of the following conditions:

                  (i)   Representations and Warranties.  The representations
and warranties of the Investor at the Closing contained herein shall be true
and correct in all material respects as of the date when made and as of the
Closing as though made on and as of such date;

                  (ii)  Performance.  The Investor at the Closing shall have
performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by the Transaction Documents to be
performed, satisfied or complied with by the Investor at or prior to the
Closing;

                  (iii) No Injunction.  No statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent
jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents; and

                  (iv)  Investor Deliverables.  The Investor at the Closing
shall have delivered its Investor Deliverables in accordance with
Section 2(b)(ii).

      6.    Miscellaneous

            (a)   Fees and Expenses.  Each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and
all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of the Transaction Documents.
The Company shall pay all stamp and other taxes and duties levied in connection
with the sale of the Shares.

            (b)   Entire Agreement.  The Transaction Documents, together with
the Exhibits and Schedules thereto, contain the entire understanding of the
parties with respect to the subject matter hereof and supersede all prior
agreements, understandings, discussions and representations, oral or written,
with respect to such matters, which the parties acknowledge have been merged
into such documents, exhibits and schedules.

            (c)   Notices.  Any and all notices or other communications or
deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of (a) the date of
transmission, if such notice or communication is delivered via email, (b) the
date of transmission, if such notice or communication is delivered via facsimile
(provided the sender receives a machine-generated confirmation of successful
transmission and reasonably promptly following such transmission sends such
notice or communication via U.S. mail or overnight courier) at the facsimile
number specified in this Section prior to 6:30 p.m. (California time) on a
Trading Day, (c) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile at the facsimile number
specified in this Section on a day that is not a Trading Day or later than 6:30
p.m.

                                       19
<PAGE>

(California time) on any Trading Day, (d) the Trading Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service, or (e)
upon actual receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as follows:

            If to the Company:   JMAR Technologies, Inc.
                                 5800 Armada Drive
                                 Carlsbad, CA  92008
                                 Facsimile No.: 760-602-3299
                                 Telephone No.: 760-602-3292
                                 Attention: General Counsel;

            If to an Investor:   To the address set forth under such Investor's
                                 name on the signature pages hereof;

            With a copy to:      Salah M. Hassanein
                                 ____________________
                                 ____________________

or such other address as may be designated in writing hereafter, in the same
manner, by such Person.

            (d)   Amendments; Waivers; No Additional Consideration.  No
provision of this Agreement may be waived or amended except in a written
instrument signed by the Company and the Investor.  No waiver of any default
with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent
default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder
in any manner impair the exercise of any such right.  No consideration shall be
offered or paid to the Investor to amend or consent to a waiver or modification
of any provision of any Transaction Document. unless the same consideration is
also offered to all Investors who then hold Shares.

            (e)   Construction.  The headings herein are for convenience only,
do not constitute a part of this Agreement and shall not be deemed to limit or
affect any of the provisions hereof.  The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.
This Agreement shall be construed as if drafted jointly by the parties, and no
presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement or any of the
Transaction Documents.

            (f)   Successors and Assigns.  This Agreement shall be binding upon
and inure to the benefit of the parties and their successors and permitted
assigns.  Other than in connection with a merger, consolidation, sale of all or
substantially all of the Company's assets or other similar change in control
transaction, the Company may not assign this Agreement or any rights or
obligations hereunder without the prior written consent of the Investor. The
Investor may assign any or all of its rights under this Agreement to any Person
to whom the Investor assigns or

                                       20
<PAGE>

transfers any Securities, provided such transferee agrees in writing to be
bound, with respect to the transferred Securities, by the provisions hereof that
apply to the "Investor."

            (g)   No Third-Party Beneficiaries.  This Agreement is intended for
the benefit of the parties hereto and their respective successors and permitted
assigns (including Permissible Transferees) and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4(f) (as to the Investor).

            (h)   Governing Law.  This Agreement shall be governed by, and
construed in accordance with, the internal laws of the State of Delaware
without regard to the choice of law principles thereof.

            (i)   Survival.  The agreements and covenants contained herein
shall survive the Closing and the delivery of the Securities.  The
representations and warranties shall survive until the first anniversary of the
Closing.

            (j)   Execution.  This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the
same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart.  In the event that any signature is
delivered by facsimile transmission, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile signature page
were an original thereof.

            (k)   Severability.  If any provision of this Agreement is held to
be invalid or unenforceable in any respect, the validity and enforceability of
the remaining terms and provisions of this Agreement shall not in any way be
affected or impaired thereby and the parties will attempt to agree upon a valid
and enforceable provision that is a reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Agreement.

            (l)   Rescission and Withdrawal Right.  Notwithstanding anything to
the contrary contained in (and without limiting any similar provisions of) the
Transaction Documents, whenever the Investor exercises a right, election,
demand or option under a Transaction Document and the Company does not timely
perform its related obligations within the periods therein provided, then the
Investor may rescind or withdraw, in its sole discretion from time to time upon
written notice to the Company, any relevant notice, demand or election in whole
or in part without prejudice to its future actions and rights.

            (m)   Replacement of Securities.  If any certificate or instrument
evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon
cancellation thereof, or in lieu of and substitution therefor, a new
certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and customary
and reasonable indemnity, if requested.  The applicants for a new certificate
or instrument under such circumstances shall also pay any reasonable third-
party costs associated with the issuance of such replacement Securities.  If a
replacement certificate or instrument evidencing any Securities

                                       21
<PAGE>

is requested due to a mutilation thereof, the Company may require delivery of
such mutilated certificate or instrument as a condition precedent to any
issuance of a replacement.

            (n)   Remedies.  In addition to being entitled to exercise all
rights provided herein or granted by law, including recovery of damages, the
Investor and the Company will be entitled to specific performance under the
Transaction Documents.  The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of
obligations described in the foregoing sentence and hereby agrees to waive in
any action for specific performance of any such obligation the defense that a
remedy at law would be adequate.

            (o)   Payment Set Aside.  To the extent that the Company makes a
payment or payments to the Investor pursuant to any Transaction Document or the
Investor enforces or exercises its rights thereunder, and such payment or
payments or the proceeds of such enforcement or exercise or any part thereof
are subsequently invalidated, declared to be fraudulent or preferential, set
aside, recovered from, disgorged by or are required to be refunded, repaid or
otherwise restored to the Company, a trustee, receiver or any other person
under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of
any such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.

            (p)   Limitation of Liability.  Notwithstanding anything herein to
the contrary, the Company acknowledges and agrees that the liability of the
Investor arising directly or indirectly, under any Transaction Document of any
and every nature whatsoever shall be satisfied solely out of the assets of the
Investor, and that no trustee, officer, other investment vehicle or any other
Affiliate of the Investor or the Investor, shareholder or holder of shares of
beneficial interest of the Investor shall be personally liable for any
liabilities of the Investor.

            (q)   Acknowledgement.  The Investor and the Company acknowledge
that:  (i) they have read this Agreement; (ii) they have been represented in
the preparation, negotiation and execution of this Agreement by legal counsel
of their own choice or have voluntarily declined to seek such counsel; and
(iii) they understand the terms and consequences of this Agreement and are
fully aware of the legal and binding effect of this Agreement.

                  REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
                            SIGNATURE PAGES FOLLOW

                                       22
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Securities
Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

                                    JMAR TECHNOLOGIES, INC.

                                    By:  /s/ RONALD A. WALROD
                                       Name:  Ronald A. Walrod
                                       Title:   Chief Executive Officer

                                    Address: 5800 Armada Drive
                                             Carlsbad, CA 92008

                                    POINTSOURCE TECHNOLOGIES, LLC

                                    By:   /s/ SALAH M. HASSANEIN
                                       Name:  Salah M. Hassanein
                                       Title:  Chairman and Chief Executive
                                       Officer

                                    Address: 514 Via de la Valle, Suite 207
                                             Solana Beach, CA 92075
                                             Telephone: (858) 509-7979
                                             Facsimile: (858) 509-0708<PAGE>

                                                                     EXHIBIT 4.6

                                FORM OF WARRANT

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN
REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS.  SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR
OTHERWISE DISPOSED OF WITHOUT EITHER (I) AN EFFECTIVE REGISTRATION STATEMENT
FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (II) AN
OPINION OF COUNSEL, IN A FORM REASONABLE ACCEPTABLE TO THE COMPANY, THAT SUCH
TRANSFER MAY BE MADE WITHOUT REGISTRATION OR QUALIFICATION UNDER SAID ACT OR
(III) SUCH TRANSFER BEING MADE PURSUANT TO RULE 144 UNDER SAID ACT.
NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY
THE SECURITIES.

                            JMAR TECHNOLOGIES, INC.

                                    WARRANT

Warrant No.: __________
Number of Shares: _____________
Date of Issuance: February 1, 2005 ("ISSUANCE DATE")

JMAR Technologies, Inc., a Delaware corporation (the "COMPANY"), hereby
certifies that, for value received, the receipt and sufficiency of which are
hereby acknowledged, [ASSIGNEES OF SOURCE CAPITAL GROUP, INC.], the registered
holder hereof or its permitted assigns (the "HOLDER"), is entitled, subject to
the terms set forth below, to purchase from the Company, at the Exercise Price
(as defined below) then in effect, at any time or times on or after the date
hereof, but not after 11:59 p.m., New York Time, on the Expiration Date (as
defined below), [One Hundred Eight Thousand Eight Hundred Seventy-One
(108,871)] fully paid nonassessable shares of Common Stock (as defined below)
(the "WARRANT SHARES").  Except as otherwise defined herein, capitalized terms
in this Warrant shall have the meanings set forth in Section 15.

      1.    EXERCISE OF WARRANT.

            (a)   Mechanics of Exercise.  Subject to the terms and conditions
hereof (including, without limitation, the limitations set forth in Section
1(f)), this Warrant may be exercised by the Holder on any day on or after the
date hereof, in whole or in part, by (i) delivery of a written notice, in the
form attached hereto as Exhibit A (the "EXERCISE NOTICE"), of the Holder's
election to exercise this Warrant and (ii) (A) payment to the Company of an
amount equal to the applicable Exercise Price multiplied by the number of
Warrant Shares as to which this Warrant is being exercised (the "AGGREGATE
EXERCISE PRICE") in cash or wire transfer of immediately available funds or (B)
by notifying the Company that this Warrant is being
<PAGE>
exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).
The Holder shall not be required to deliver the original Warrant in order to
effect an exercise hereunder. Execution and delivery of the Exercise Notice with
respect to less than all of the Warrant Shares shall have the same effect as
cancellation of the original Warrant and issuance of a new Warrant evidencing
the right to purchase the remaining number of Warrant Shares. On or before the
first Business Day following the date on which the Company has received each of
the Exercise Notice and the Aggregate Exercise Price (or notice of a Cashless
Exercise) (the "EXERCISE DELIVERY DOCUMENTS"), the Company shall transmit by
facsimile an acknowledgment of confirmation of receipt of the Exercise Delivery
Documents to the Holder and the Company's transfer agent (the "TRANSFER AGENT").
On or before the third Business Day following the date on which the Company has
received all of the Exercise Delivery Documents (the "SHARE DELIVERY DATE"), the
Company shall (X) provided that the Transfer Agent is participating in The
Depository Trust Company ("DTC") Fast Automated Securities Transfer Program,
upon the request of the Holder, credit such aggregate number of shares of Common
Stock to which the Holder is entitled pursuant to such exercise to the Holder's
or its designee's balance account with DTC through its Deposit Withdrawal Agent
Commission system, or (Y) if the Transfer Agent is not participating in the DTC
Fast Automated Securities Transfer Program, issue and dispatch by overnight
courier to the address as specified in the Exercise Notice, a certificate,
registered in the Company's share register in the name of the Holder or its
designee, for the number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise. Upon delivery of the Exercise Notice and
Aggregate Exercise Price referred to in clause (ii)(A) above or notification to
the Company of a Cashless Exercise referred to in Section 1(d), the Holder shall
be deemed for all corporate purposes to have become the holder of record of the
Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date of delivery of the certificates evidencing such Warrant
Shares. If this Warrant is submitted in connection with any exercise pursuant to
this Section 1(a) and the number of Warrant Shares represented by this Warrant
submitted for exercise is greater than the number of Warrant Shares being
acquired upon an exercise, then the Company shall as soon as practicable and in
no event later than three Business Days after any exercise and at its own
expense, issue a new Warrant (in accordance with Section 7(d)) representing the
right to purchase the number of Warrant Shares purchasable immediately prior to
such exercise under this Warrant, less the number of Warrant Shares with respect
to which this Warrant is exercised. No fractional shares of Common Stock are to
be issued upon the exercise of this Warrant, but rather the number of shares of
Common Stock to be issued shall be rounded up to the nearest whole number. The
Company shall pay any and all taxes which may be payable with respect to the
issuance and delivery of Warrant Shares upon exercise of this Warrant.

            (b)   Exercise Price.  For purposes of this Warrant, "EXERCISE
PRICE" means $1.80, subject to adjustment as provided herein.

            (c)   Cashless Exercise.  Notwithstanding anything contained herein
to the contrary, if a Registration Statement covering the Warrant Shares that
are the subject of the Exercise Notice (the "UNAVAILABLE WARRANT SHARES") is
not available for the resale of such Unavailable Warrant Shares, the Holder
may, in its sole discretion, exercise this Warrant in whole or in part and, in
lieu of making the cash payment otherwise contemplated to be made to the
Company upon such exercise in payment of the Aggregate Exercise Price, elect
instead to

                                      -2-
<PAGE>

receive upon such exercise the "Net Number" of shares of Common Stock determined
according to the following formula (a "CASHLESS EXERCISE"):

                  Net Number = (A x B) - (A x C)
                               -----------------
                                       B

                  For purposes of the foregoing formula:

            A = the total number of shares with respect to which this Warrant
            is then being exercised.

            B = the Closing Sale Price of the shares of Common Stock (as
            reported by Bloomberg) on the date immediately preceding the date
            of the Exercise Notice.

            C= the Exercise Price then in effect for the applicable Warrant
            Shares at the time of such exercise.

            (d)   Disputes.  In the case of a dispute as to the determination
of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that
are not disputed and resolve such dispute in accordance with Section 12.

            (e)   Limitations on Exercises.

                  (i)   Beneficial Ownership.  The Company shall not effect the
      exercise of this Warrant, and the Holder shall not have the right to
      exercise this Warrant, to the extent that after giving effect to such
      exercise, such Person (together with such Person's affiliates) would
      beneficially own in excess of 4.99% of the shares of Common Stock
      outstanding immediately after giving effect to such exercise.  For
      purposes of the foregoing sentence, the aggregate number of shares of
      Common Stock beneficially owned by such Person and its affiliates shall
      include the number of shares of Common Stock issuable upon exercise of
      this Warrant with respect to which the determination of such sentence is
      being made, but shall exclude shares of Common Stock which would be
      issuable upon (i) exercise of the remaining, unexercised portion of this
      Warrant beneficially owned by such Person and its affiliates and (ii)
      exercise or conversion of the unexercised or unconverted portion of any
      other securities of the Company beneficially owned by such Person and its
      affiliates (including, without limitation, any convertible notes or
      convertible preferred stock or warrants) subject to a limitation on
      conversion or exercise analogous to the limitation contained herein.
      Except as set forth in the preceding sentence, for purposes of this
      paragraph, beneficial ownership shall be calculated in accordance with
      Section 13(d) of the Securities Exchange Act of 1934, as amended.  For
      purposes of this Warrant, in determining the number of outstanding shares
      of Common Stock, the Holder may rely on the number of outstanding shares
      of Common Stock as reflected in (1) the Company's most recent Form 10-K,
      Form 10-Q, Current Report on Form 8-K or other public filing with the
      Securities and Exchange Commission, as the case may be, (2) a more recent
      public announcement by the Company or (3) any other

                                      -3-
<PAGE>

     notice by the Company or the Transfer Agent setting forth the number of
     shares of Common Stock outstanding. For any reason at any time, upon the
     written or oral request of the Holder, the Company shall within one
     Business Day confirm orally and in writing to the Holder the number of
     shares of Common Stock then outstanding. In any case, the number of
     outstanding shares of Common Stock shall be determined after giving effect
     to the conversion or exercise of securities of the Company, including the
     SPA Warrants, by the Holder and its affiliates since the date as of which
     such number of outstanding shares of Common Stock was reported.

                  (ii)  Principal Market Regulation.  The Company shall not be
      obligated to issue any shares of Common Stock upon exercise of this
      Warrant if the issuance of such shares of Common Stock would exceed that
      number of shares of Common Stock which the Company may issue upon
      exercise of this Warrant without breaching the Company's obligations
      under the rules or regulations of the Principal Market (the "EXCHANGE
      CAP"), except that such limitation shall not apply in the event that the
      Company (A) obtains the approval of its shareholders as required by the
      applicable rules of the Principal Market for issuances of shares of
      Common Stock in excess of such amount or (B) obtains a written opinion
      from outside counsel to the Company that such approval is not required,
      which opinion shall be reasonably satisfactory to the Required Holders.
      Until such approval or written opinion is obtained, no Buyer shall be
      issued, upon exercise of any SPA Warrants, shares of Common Stock in an
      amount greater than the product of the Exchange Cap multiplied by a
      fraction, the numerator of which is the total number of shares of Common
      Stock issued to such Buyer pursuant to the Securities Purchase Agreement
      on the Issuance Date and the denominator of which is the aggregate number
      of shares of Common Stock issued to the Buyers pursuant to the Securities
      Purchase Agreement on the Issuance Date (with respect to each Buyer, the
      "EXCHANGE CAP ALLOCATION").  In the event that any Buyer shall sell or
      otherwise transfer any of such Buyer's SPA Warrants, the transferee shall
      be allocated a pro rata portion of such Buyer's Exchange Cap Allocation,
      and the restrictions of the prior sentence shall apply to such transferee
      with respect to the portion of the Exchange Cap Allocation allocated to
      such transferee.  In the event that any holder of SPA Warrants shall
      exercise all of such holder's SPA Warrants into a number of shares of
      Common Stock which, in the aggregate, is less than such holder's Exchange
      Cap Allocation, then the difference between such holder's Exchange Cap
      Allocation and the number of shares of Common Stock actually issued to
      such holder shall be allocated to the respective Exchange Cap Allocations
      of the remaining holders of SPA Warrants on a pro rata basis in
      proportion to the shares of Common Stock underlying the SPA Warrants then
      held by each such holder.  In the event that the Company is prohibited
      from issuing any Warrant Shares for which an Exercise Notice has been
      received as a result of the operation of this Section 1(f)(ii), the
      Company shall pay cash in exchange for cancellation of such Warrant
      Shares, at a price per Warrant Share equal to the difference between the
      Closing Sale Price and the Exercise Price as of the date of the attempted
      exercise.

      2.    ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.

            Adjustment upon Subdivision or Combination of Common Stock.  If the

                                      -4-
<PAGE>

Company at any time after the date of issuance of this Warrant subdivides (by
any stock split, stock dividend, recapitalization or otherwise) one or more
classes of its outstanding shares of Common Stock into a greater number of
shares, the Exercise Price in effect immediately prior to such subdivision will
be proportionately reduced and the number of Warrant Shares will be
proportionately increased. If the Company at any time after the date of issuance
of this Warrant combines (by combination, reverse stock split or otherwise) one
or more classes of its outstanding shares of Common Stock into a smaller number
of shares, the Exercise Price in effect immediately prior to such combination
will be proportionately increased and the number of Warrant Shares will be
proportionately decreased. Any adjustment under this Section 2(b) shall become
effective at the close of business on the date the subdivision or combination
becomes effective.

      3.    RIGHTS UPON DISTRIBUTION OF ASSETS.

            If the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of
Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate
rearrangement or other similar transaction) (a "DISTRIBUTION"), at any time
after the issuance of this Warrant, then, in each such case:

            (a)   any Exercise Price in effect immediately prior to the close
of business on the record date fixed for the determination of holders of Common
Stock entitled to receive the Distribution shall be reduced, effective as of
the close of business on such record date, to a price determined by multiplying
such Exercise Price by a fraction of which (i) the numerator shall be the
Closing Bid Price of the Common Stock on the trading day immediately preceding
such record date minus the value of the Distribution (as determined in good
faith by the Company's Board of Directors) applicable to one share of Common
Stock, and (ii) the denominator shall be the Closing Bid Price of the Common
Stock on the trading day immediately preceding such record date; and

            (b)   the number of Warrant Shares shall be increased to a number
of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination
of holders of Common Stock entitled to receive the Distribution multiplied by
the reciprocal of the fraction set forth in the immediately preceding paragraph
(a); provided that in the event that the Distribution is of common stock
("OTHER COMMON STOCK") of a company whose common stock is traded on a national
securities exchange or a national automated quotation system, then the holder
of this Warrant may elect to receive a warrant to purchase Other Common Stock
in lieu of an increase in the number of Warrant Shares, the terms of which
shall be identical to those of this Warrant, except that such warrant shall be
exercisable into the number of shares of Other Common Stock that would have
been payable to the holder of this Warrant pursuant to the Distribution had the
holder exercised this Warrant immediately prior to such record date and with an
aggregate exercise price equal to the product of the amount by which the
exercise price of this Warrant was decreased with respect to the Distribution
pursuant to the terms of the immediately preceding paragraph (a) and the number
of Warrant Shares calculated in accordance with the first part of this
paragraph (b).

                                      -5-
<PAGE>

      4.    PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.

            (a)   Purchase Rights.  In addition to any adjustments pursuant to
Section 2 above, if at any time the Company grants, issues or sells any
Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of
shares of Common Stock (the "PURCHASE RIGHTS"), then the Holder will be
entitled to acquire, upon the terms applicable to such Purchase Rights, the
aggregate Purchase Rights which the Holder could have acquired if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on the exercise of this
Warrant) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be
determined for the grant, issue or sale of such Purchase Rights.

            (b)   Fundamental Transactions.  The Company shall not enter into
or be party to a Fundamental Transaction unless (i) the Successor Entity assumes
in writing all of the obligations of the Company under this Warrant and the
other Transaction Documents in accordance with the provisions of this Section
(4)(b) pursuant to written agreements in form and substance satisfactory to the
Required Holders and approved by the Required Holders prior to such Fundamental
Transaction, including agreements to deliver to each holder of Warrants in
exchange for such Warrants a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Warrant,
including, without limitation, an adjusted exercise price equal to the value for
the shares of Common Stock reflected by the terms of such Fundamental
Transaction, and exercisable for a corresponding number of shares of capital
stock equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of
this Warrant) prior to such Fundamental Transaction, and satisfactory to the
Required Holders and (ii) the Successor Entity (including its Parent Entity) is
a publicly traded corporation whose common stock is quoted on or listed for
trading on an Eligible Market.  Upon the occurrence of any Fundamental
Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of
this Warrant referring to the "Company" shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume
all of the obligations of the Company under this Warrant with the same effect as
if such Successor Entity had been named as the Company herein.  Upon
consummation of the Fundamental Transaction, the Successor Entity shall deliver
to the Holder confirmation that there shall be issued upon exercise of this
Warrant at any time after the consummation of the Fundamental Transaction, in
lieu of the shares of the Common Stock (or other securities, cash, assets or
other property) purchasable upon the exercise of the Warrant prior to such
Fundamental Transaction, such shares of stock, securities, cash, assets or any
other property whatsoever (including warrants or other purchase or subscription
rights) which the Holder would have been entitled to receive upon the happening
of such Fundamental Transaction had this Warrant been converted immediately
prior to such Fundamental Transaction, as adjusted in accordance with the
provisions of this Warrant. In addition to and not in substitution for any other
rights hereunder, prior to the consummation of any Fundamental Transaction
pursuant to which holders of shares of Common Stock are entitled to receive
securities or other assets with respect to or in exchange for shares of Common
Stock (a "CORPORATE EVENT"), the Company shall make appropriate provision to
insure that the Holder will thereafter have the right to receive

                                      -6-
<PAGE>
upon an exercise of this Warrant at any time after the consummation of the
Fundamental Transaction but prior to the Expiration Date, in lieu of the shares
of the Common Stock (or other securities, cash, assets or other property)
purchasable upon the exercise of the Warrant prior to such Fundamental
Transaction, such shares of stock, securities, cash, assets or any other
property whatsoever (including warrants or other purchase or subscription
rights) which the Holder would have been entitled to receive upon the happening
of such Fundamental Transaction had the Warrant been exercised immediately prior
to such Fundamental Transaction. Provision made pursuant to the preceding
sentence shall be in a form and substance reasonably satisfactory to the
Required Holders. The provisions of this Section shall apply similarly and
equally to successive Fundamental Transactions and Corporate Events and shall be
applied without regard to any limitations on the exercise of this Warrant.

      5.    NONCIRCUMVENTION.

            The Company hereby covenants and agrees that the Company will not,
by amendment of its Certificate of Incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of
securities, or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, and will at all
times in good faith carry out all the provisions of this Warrant and take all
action as may be required to protect the rights of the holder of this Warrant.
Without limiting the generality of the foregoing, the Company (i) will not
increase the par value of any shares of Common Stock receivable upon the
exercise of this Warrant above the Exercise Price then in effect, (ii) will
take all such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of
Common Stock upon the exercise of this Warrant, and (iii) will, so long as any
of the SPA Warrants are outstanding, take all action necessary to reserve and
keep available out of its authorized and unissued Common Stock, solely for the
purpose of effecting the exercise of the SPA Warrants, 100% of the number of
shares of Common Stock as shall from time to time be necessary to effect the
exercise of the SPA Warrants then outstanding (without regard to any
limitations on exercise).

      6.    HOLDER NOT DEEMED A STOCKHOLDER.

            Except as otherwise specifically provided herein, no holder, solely
in such Person's capacity as a holder, of this Warrant shall be entitled to
vote or receive dividends or be deemed the holder of shares of the Company for
any purpose, nor shall anything contained in this Warrant be construed to
confer upon the holder hereof, solely in such Person's capacity as a holder of
this Warrant, any of the rights of a shareholder of the Company or any right to
vote, give or withhold consent to any corporate action (whether any
reorganization, issue of stock, reclassification of stock, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the holder of
this Warrant of the Warrant Shares which such Person is then entitled to
receive upon the due exercise of this Warrant.  In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on such holder
to purchase any securities (upon exercise of this Warrant or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the
Company or by creditors of the Company.  Notwithstanding this Section 6, the
Company will provide the holder of this Warrant with copies of the same notices
and other information given to the stockholders of the Company generally,
contemporaneously with the

                                      -7-
<PAGE>

giving thereof to the stockholders, except for those notices and other
information contained within the SEC Documents and available on the SEC's EDGAR
system.

      7.    REISSUANCE OF WARRANTS.

            (a)   Transfer of Warrant.  If this Warrant is to be transferred,
the holder shall surrender this Warrant to the Company, whereupon the Company
will forthwith issue and deliver upon the order of the holder of this Warrant a
new Warrant (in accordance with Section 7(d)), registered as the holder of this
Warrant may request, representing the right to purchase the number of Warrant
Shares being transferred by the Holder and, if less then the total number of
Warrant Shares then underlying this Warrant is being transferred, a new Warrant
(in accordance with Section 7(d)) to the holder of this Warrant representing
the right to purchase the number of Warrant Shares not being transferred.

            (b)   Lost, Stolen or Mutilated Warrant.  Upon receipt by the
Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or
destruction, of any indemnification undertaking by the holder of this Warrant
to the Company in customary form and, in the case of mutilation, upon surrender
and cancellation of this Warrant, the Company shall execute and deliver to the
Holder a new Warrant (in accordance with Section 7(d)) representing the right
to purchase the Warrant Shares then underlying this Warrant.

            (c)   Warrant Exchangeable for Multiple Warrants.  This Warrant is
exchangeable, upon the surrender hereof by the Holder at the principal office
of the Company, for a new Warrant or Warrants (in accordance with Section 7(d))
representing in the aggregate the right to purchase the number of Warrant
Shares then underlying this Warrant, and each such new Warrant will represent
the right to purchase such portion of such Warrant Shares as is designated by
the holder of this Warrant at the time of such surrender; provided, however,
that no Warrants for fractional shares of Common Stock shall be given.

            (d)   Issuance of New Warrants.  Whenever the Company is required
to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as
indicated on the face of such new Warrant, the right to purchase the Warrant
Shares then underlying this Warrant (or in the case of a new Warrant being
issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated
by the holder of this Warrant which, when added to the number of shares of
Common Stock underlying the other new Warrants issued in connection with such
issuance, does not exceed the number of Warrant Shares then underlying this
Warrant), (iii) shall have an issuance date, as indicated on the face of such
new Warrant which is the same as the Issuance Date, and (iv) shall have the
same rights and conditions as this Warrant.

      8.    NOTICES.

            Whenever notice is required to be given under this Warrant, unless
otherwise provided herein, such notice shall be given in accordance with
Section 9(f) of the Securities Purchase Agreement.  The Company shall provide
the holder of this Warrant with prompt written notice of all actions taken
pursuant to this Warrant, including in reasonable detail a

                                      -8-
<PAGE>

description of such action and the reason therefore. Without limiting the
generality of the foregoing, the Company will give written notice to the holder
of this Warrant (i) immediately upon any adjustment of the Exercise Price,
setting forth in reasonable detail, and certifying, the calculation of such
adjustment and (ii) at least fifteen days prior to the date on which the Company
closes its books or takes a record (A) with respect to any dividend or
distribution upon the Common Stock or (B) for determining rights to vote with
respect to any Fundamental Transaction, dissolution or liquidation, provided in
each case that such information shall be made known to the public prior to or in
conjunction with such notice being provided to such holder.

      9.    AMENDMENT AND WAIVER.

            Except as otherwise provided herein, the provisions of this Warrant
may be amended and the Company may take any action herein prohibited, or omit
to perform any act herein required to be performed by it, only if the Company
has obtained the written consent of the holders of SPA Warrants representing at
least a majority of the shares of Common Stock obtainable upon exercise of the
SPA Warrants then outstanding; provided that no such action may increase the
exercise price of any SPA Warrant or decrease the number of shares or class of
stock obtainable upon exercise of any SPA Warrant without the written consent
of the holder of this Warrant.  No such amendment shall be effective to the
extent that it applies to less than all of the holders of the SPA Warrants then
outstanding.

      10.   GOVERNING LAW.

            This Warrant shall be construed and enforced in accordance with,
and all questions concerning the construction, validity, interpretation and
performance of this Warrant shall be governed by, the internal laws of the
State of Delaware, without giving effect to any choice of law or conflict of
law provision or rule (whether of the State of Delaware or any other
jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of Delaware.

      11.   CONSTRUCTION; HEADINGS.

            This Warrant shall be deemed to be jointly drafted by the Company
and all the Buyers and shall not be construed against any person as the drafter
hereof.  The headings of this Warrant are for convenience of reference and
shall not form part of, or affect the interpretation of, this Warrant.

      12.   DISPUTE RESOLUTION.

            In the case of a dispute as to the determination of the Exercise
Price or the arithmetic calculation of the Warrant Shares, the Company shall
submit the disputed determinations or arithmetic calculations via facsimile
within two Business Days of receipt of the Exercise Notice giving rise to such
dispute, as the case may be, to the holder of this Warrant.  If the holder of
this Warrant and the Company are unable to agree upon such determination or
calculation of the Exercise Price or the Warrant Shares within three Business
Days of such disputed determination or arithmetic calculation being submitted
to the Holder, then the Company shall, within two Business Days submit via
facsimile (a) the disputed determination of the Exercise Price to an
independent, reputable investment bank selected by the Company and

                                      -9-
<PAGE>

approved by the holder of this Warrant or (b) the disputed arithmetic
calculation of the Warrant Shares to the Company's independent, outside
accountant. The Company shall cause at its expense the investment bank or the
accountant, as the case may be, to perform the determinations or calculations
and notify the Company and the Holder of the results no later than ten Business
Days from the time it receives the disputed determinations or calculations. Such
investment bank's or accountant's determination or calculation, as the case may
be, shall be binding upon all parties absent demonstrable error.

      13.   REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF.

            The remedies provided in this Warrant shall be cumulative and in
addition to all other remedies available under this Warrant, at law or in
equity (including a decree of specific performance and/or other injunctive
relief), and nothing herein shall limit the right of the holder of this Warrant
to pursue actual damages for any failure by the Company to comply with the
terms of this Warrant.  The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the holder of this Warrant
and that the remedy at law for any such breach may be inadequate.  The Company
therefore agrees that, in the event of any such breach or threatened breach,
the holder of this Warrant shall be entitled, in addition to all other
available remedies, to an injunction restraining any breach, without the
necessity of showing economic loss and without any bond or other security being
required.

      14.   TRANSFER.

            This Warrant may be offered for sale, sold, transferred or assigned
without the consent of the Company, except as may otherwise be required by
Section 2(f) of the Securities Purchase Agreement.

      15.   CERTAIN DEFINITIONS.

            For purposes of this Warrant, the following terms shall have the
following meanings:

            (a)   "BLOOMBERG" means Bloomberg Financial Markets.

            (b)   "BUSINESS DAY" means any day other than Saturday, Sunday or
other day on which commercial banks in The City of New York are authorized or
required by law to remain closed.

            (c)   "CLOSING BID PRICE" and "CLOSING SALE PRICE" means, for any
security as of any date, the last closing bid price and last closing trade
price, respectively, for such security on the Principal Market, as reported by
Bloomberg, or, if the Principal Market begins to operate on an extended hours
basis and does not designate the closing bid price or the closing trade price,
as the case may be, then the last bid price or last trade price, respectively,
of such security prior to 4:00:00 p.m., New York Time, as reported by
Bloomberg, or, if the Principal Market is not the principal securities exchange
or trading market for such security, the last closing bid price or last trade
price, respectively, of such security on the principal securities exchange or
trading market where such security is listed or traded as reported by
Bloomberg, or if the foregoing do not

                                      -10-
<PAGE>

apply, the last closing bid price or last trade price, respectively, of such
security in the over-the-counter market on the electronic bulletin board for
such security as reported by Bloomberg, or, if no closing bid price or last
trade price, respectively, is reported for such security by Bloomberg, the
average of the bid prices, or the ask prices, respectively, of any market makers
for such security as reported in the "pink sheets" by Pink Sheets LLC (formerly
the National Quotation Bureau, Inc.). If the Closing Bid Price or the Closing
Sale Price cannot be calculated for a security on a particular date on any of
the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the
case may be, of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder
are unable to agree upon the fair market value of such security, then such
dispute shall be resolved pursuant to Section 12. All such determinations to be
appropriately adjusted for any stock dividend, stock split, stock combination or
other similar transaction during the applicable calculation period.

            (d)   "COMMON STOCK" means (i) the Company's common stock, par
value $0.01 per share, and (ii) any capital stock into which such Common Stock
shall have been changed or any capital stock resulting from a reclassification
of such Common Stock.

            (e)   "CONVERTIBLE SECURITIES" means any stock or securities (other
than Options) directly or indirectly convertible into or exercisable or
exchangeable for Common Stock.

            (f)   "ELIGIBLE MARKET" means means The New York Stock Exchange,
Inc., the American Stock Exchange, the Nasdaq National Market or the Principal
Market.

            (g)   "EXPIRATION DATE" means February 1, 2010.

            (h)   "FUNDAMENTAL TRANSACTION" means that the Company shall,
directly or indirectly, in one or more related transactions, (i) consolidate or
merge with or into (whether or not the Company is the surviving corporation)
another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of
all or substantially all of the properties or assets of the Company to another
Person, or (iii) allow another Person to make a purchase, tender or exchange
offer that is accepted by the holders of more than the 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the
Person or Persons making or party to, or associated or affiliated with the
Persons making or party to, such purchase, tender or exchange offer), or (iv)
consummate a stock purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of
arrangement) with another Person whereby such other Person acquires more than
the 50% of the outstanding shares of Common Stock (not including any shares of
Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock
purchase agreement or other business combination), or (v) reorganize,
recapitalize or reclassify its Common Stock.

            (i)   "OPTIONS" means any rights, warrants or options to subscribe
for or purchase Common Stock or Convertible Securities.

            (j)   "PARENT ENTITY" of a Person means an entity that, directly or
indirectly, controls the applicable Person and whose common stock or equivalent
equity security is quoted

                                      -11-
<PAGE>

or listed on an Eligible Market, or, if there is more than one such Person or
Parent Entity, the Person or Parent Entity with the largest public market
capitalization as of the date of consummation of the Fundamental Transaction.

            (k)   "PERSON" means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated
organization, any other entity and a government or any department or agency
thereof.

            (l)   "PRINCIPAL MARKET" means The NASDAQ SmallCap Market.

            (m)   "REQUIRED HOLDERS" means the holders of the SPA Warrants
representing at least a majority of shares of Common Stock underlying the SPA
Warrants then outstanding.

            (n)   "SUCCESSOR ENTITY" means the Person (or, if so elected by the
Required Holders, the Parent Entity) formed by, resulting from or surviving any
Fundamental Transaction or the Person (or, if so elected by the Required
Holders, the Parent Entity) with which such Fundamental Transaction shall have
been entered into.

                           [SIGNATURE PAGE FOLLOWS]

                                      -12-
<PAGE>

      IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed as of the Issuance Date set out above.

                                           JMAR TECHNOLOGIES, INC.

                                           By:_________________________________
                                                 Name:
                                                 Title:

<PAGE>

                                                                      EXHIBIT A

                                EXERCISE NOTICE

           TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
                                    WARRANT

                            JMAR TECHNOLOGIES, INC.

To:   JMAR Technologies, Inc.

      The undersigned is the holder of Warrant No. _____ (the "WARRANT") issued
by JMAR Technologies, Inc., a Delaware corporation (the "COMPANY").
Capitalized terms used herein and not otherwise defined shall have the
respective meanings set forth in the Warrant.

      1.    The Warrant is currently exercisable to purchase a total of
____________ Warrant Shares.

      2.     The undersigned holder hereby exercises its right to purchase
______________ Warrant Shares pursuant to the Warrant.

      3.    The Holder intends that payment of the Exercise Price shall be made
as:

            ______a "Cash Exercise" with respect to _________________ Warrant
Shares; and/or

            ______a "Cashless Exercise" with respect to _______________ Warrant
Shares.

      4.    Pursuant to this exercise, the Company shall deliver to the holder
__________ Warrant Shares in accordance with the terms of the Warrant.

      5.    Following this exercise, the Warrant shall be exercisable to
purchase a total of ________________ Warrant Shares.

      Please issue the Warrant Shares in the following name and to the
following address:

      Issue to:________________________________________________________________
               ________________________________________________________________
               ________________________________________________________________
      Account Number: _________________________________________________________
        (if electronic book entry transfer)

      DTC Participant Number:__________________________________________________
        (if electronic book entry transfer)

Date: _______________ __, ______

Name of Registered Holder

By:___________________________
      Name:
      Title:

<PAGE>

                              FORM OF ASSIGNMENT

      [To be completed and signed only upon transfer of Warrant]

      FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto ________________________________ the right represented by the within
Warrant to purchase  ____________ shares of Common Stock of JMAR Technologies,
Inc. to which the within Warrant relates and appoints ________________ attorney
to transfer said right on the books of JMAR Technologies, Inc. with full power
of substitution in the premises.

Dated: ___________, ____

                             ___________________________________________________
                             (Signature must conform in all respects to name of
                             holder as specified on the face of the Warrant)

                             ____________________________________
                             Address of Transferee

                             ____________________________________

                             ____________________________________

In the presence of:

_________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}]]